Yongjin Xu

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Wei‐Sheng Huang, Shuangying Liu, Dong Zou et al. · Journal of Medicinal Chemistry · 2016 · 392 citations · Full text

Drug Target, Anaplastic Lymphoma Kinase, Tumor Biology +18

Using Molecular Equivalence Numbers To Visually Explore Structural Features that Distinguish Chemical Libraries

Yongjin Xu, Mark A. Johnson · Journal of Chemical Information and Computer Sciences · 2002 · 110 citations

Engineering, Molecular Biology, Computational Chemistry +16

Fragment Growing and Linking Lead to Novel Nanomolar Lactate Dehydrogenase Inhibitors

Anna Kohlmann, Stephan G. Zech, Feng Li et al. · Journal of Medicinal Chemistry · 2013 · 83 citations · Full text

Algorithm for Naming Molecular Equivalence Classes Represented by Labeled Pseudographs

Yongjin Xu, Mark A. Johnson · Journal of Chemical Information and Computer Sciences · 2001 · 80 citations

Engineering, Structural Pattern Recognition, Morgan Algorithm +20

Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton’s Tyrosine Kinase for the Treatment of Lymphoma

Jingyu Zhang, Jinxin Che, Xiaomin Luo et al. · Journal of Medicinal Chemistry · 2022 · 50 citations · Full text